Results 91 to 100 of about 21,298 (206)

Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer

Journal of Nanobiotechnology
Background Breast cancer is the most prevalent malignant tumor among women, with hormone receptor-positive cases constituting 70%. Fulvestrant, an antagonist for these receptors, is utilized for advanced metastatic hormone receptor-positive breast cancer.
Li Zhi, Chen Cheng, Luo Jing, Peng Zhi-Ping, Yang Lu, Tian Yan, Wang Zhi-Gang, Yin Guo-Bing   +7 more
doaj   +1 more source

Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis

Frontiers in Pharmacology
ObjectiveCapivasertib, a novel pan-AKT inhibitor, shows significant antitumor activity against hormone receptor-positive advanced breast cancer. However, its cost-effectiveness of this treatment remains uncertain.
Yitian Lang, Qingqing Chai, Yan Lin, Bin Wu, Xiaoyan Liu   +4 more
doaj   +1 more source

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

Case Reports in Oncology, 2010
We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies.
H. Hawle, D. Hess, A. Mueller, B. Thuerlimann   +3 more
doaj   +1 more source

Endocrine resistance in hormone receptor positive breast cancer–from mechanism to therapy [PDF]

, 2019
The importance and role of the estrogen receptor (ER) pathway has been well-documented in both breast cancer (BC) development and progression. The treatment of choice in women with metastatic breast cancer (MBC) is classically divided into a variety of ...
Giamas, G., Giamas, G., Murphy, J.J., Murphy, J.J., Rani, A., Rani, A., Stebbing, J., Stebbing, J.   +7 more
core   +3 more sources

17β-estradiol abrogates apoptosis inhibiting PKCδ, JNK and p66Shc activation in C2C12 cells [PDF]

, 2015
17β-Estradiol (E2) protects several non-reproductive tissues from apoptosis, including skeletal muscle. Previously, we showed that E2 at physiological concentrations prevented apoptosis induced by H2O2 in skeletal myoblasts.
Ahnadi, Almeida, Armstrong, Assert, Blass, Bokoch, Boland, Bradford, Brodie, Burattini, Chambers, Chen, Chen, Corbalan-Garcia, Dionne, Gutcher, Hibi, Jackson, Jejurikar, Jejurikar, Jiang, Kikkawa, Konishi, La Colla, Laemmli, Livak, Migliaccio, Migliaccio, Milanesi, Newton, Nishizuka, Pelicci, Pellegrini, Pronsato, Razandi, Reyland, Rodriguez-Pena, Ronda, Shanmugam, Spyridopoulos, Steinberg, Takuwa, Tukey, Vasconsuelo, Vasconsuelo, Ventura, Wang, Yao, Yoshida, Yoshida   +49 more
core   +1 more source

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) [PDF]

, 2017
Background: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment.
Clément, P., Dietrich, D., Fiche, M., Goldhirsch, A., Hawle, H., Köberle, D., Nolé, F., Paridaens, R., Perey, L., Thürlimann, B., Wildiers, H., Zaman, K.   +11 more
core  

Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-Lack of association between activating AKT mutation and AKT inhibition-derived efficacy [PDF]

, 2019
This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced ...
Boix, Oliver, Hess, Dagmar, Hurvitz, Sara A, Joerger, Markus, Lagkadinou, Eleni, Ma, Cynthia, Moulder, Stacy, Ocker, Matthias, Rentzsch, Christine, Rudolph, Marion, Schneeweiss, Andreas, Thiele, Silke, Tsimberidou, Apostolia M, Varga, Andrea, Wilkinson, Gary   +14 more
core   +3 more sources

Mitochondria directly donate their membrane to form autophagosomes during a novel mechanism of parkin-associated mitophagy [PDF]

, 2014
BACKGROUND: Autophagy (macroautophagy), a cellular process of “self-eating”, segregates damaged/aged organelles into vesicles, fuses with lysosomes, and enables recycling of the digested materials.
David D Roberts, David R Soto-Pantoja, Katherine L Cook, Mones Abu-Asab, Pamela AG Clarke, Robert Clarke   +5 more
core   +1 more source

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review

Frontiers in Oncology, 2019
Introduction: Hormonal therapy in endometrial cancer (EC) is used for patients who wish to preserve fertility and for patients with advanced or recurrent disease in a palliative setting.
Willem Jan van Weelden, Leon F. A. G. Massuger, ENITEC, Johanna M. A. Pijnenborg, Andrea Romano   +4 more
doaj   +1 more source

Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells

Frontiers in Oncology
IntroductionInsulin-like growth factor binding protein-3 (IGFBP-3) exerts varying effects on estrogen receptor alpha (ERα)-positive and triple-negative breast cancer (TNBC) cells. In ERα-positive cells, IGFBP-3 is antiproliferative and proapoptotic.
Keenan L. Flynn, Yan Zheng, Janel Y. Sowers, Nefretiri J. T. Masangya, Kevin D. Houston   +4 more
doaj   +1 more source